Questcor Pharmaceuticals — Investor Presentation (November 2011)
29 slides from Questcor Pharmaceuticals's investor presentation, Nov 7, 2011
Slide 1: Questcor Investor Presentation November 2011
NASDAQ: QCOR November 2011 Exhibit 99.1 NASDAQ: QCOR November 2011
Slide 2: Safe Harbor Statement
2 Safe Harbor Statement Note: Except for the historical information contained herein, this press release contains forward-looking statements that have been made pursuant to the Private Securities Litigation Reform Act of 1995. These statements relate to future events or our future financial performa
Slide 3: Questcor: A biopharmaceutical company built around Acthar
3 Questcor A biopharmaceutical company whose product, Acthar, helps patients with serious, difficult-to-treat medical conditions A biopharmaceutical company whose product, Acthar, helps patients with serious, difficult-to-treat medical conditions
Slide 4: Questcor Overview
4 Questcor Overview Flagship Product: • Profitable, cash flow positive, $180M* in cash, debt-free • 19 approved indications Key Markets: • Multiple Sclerosis, Nephrotic Syndrome, Infantile Spasms • Combined market opportunity exceeds $1.5 billion Strategy: • Grow Acthar sales in each key market • De
Slide 5: History of Acthar
5 History of Acthar 1950 2000 2010 1952 First Approved 1950 1978 MS Flare Indication Added 2000 2001 Questcor Acquires Acthar 2010 Label Modernized 19 Indications 2007 Questcor Changes Strategy 2010
Slide 6: Significant Barriers to Entry
6 Significant Barriers to Entry Formulation Manufacturing Regulatory Business 6 Formulation Biologic Undisclosed composition Manufacturing Process complex, unique and proprietary Composition tied to process Regulatory Generic pathway unlikely Biosimilar pathway unlikely Trials likely needed Business
Slide 7: QCOR Strategy – Sell More Acthar
7 QCOR Strategy – Sell More Acthar Multiple Sclerosis (MS) Nephrotic Syndrome (NS) Infantile Spasms (IS) Systemic Lupus Erythematosus Multiple Sclerosis (MS) Nephrotic Syndrome (NS) Infantile Spasms (IS) Systemic Lupus Erythematosus
Slide 8: Acthar and MS
Acthar and MS Inadequate Response to Steroids Poor Venous Access Problematic Steroid Side Effects Acthar when “Steroids are not suitable” *Based on prescriptions written Neurodegenerative disorder Acute treatment for relapses Treatment for 1-2 weeks* $40K-$50K/Rx Inadequate Response to Steroids Poor
Slide 9: MS Scripts - Record of Consistent Growth
9 MS Scripts-Record of Consistent Growth New Paid Rxs Notes: Historical trend information is not necessarily indicative of future results. Chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the condition or are closely related to the medical condition which i
Slide 10: Monthly MS Scripts Have 160% CAGR
Monthly MS Scripts Have 160% CAGR Notes: Historical trend information is not necessarily indicative of future results. Chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the condition or are closely related to the medical condition which is the focus of the c
Slide 11: MS Trends
11 • Doubled sales force: 38 to 77 sales reps Nov 2010 • Q3-2011 results – Q3-11 new, paid Rxs up 174% vs. Q3-10 – MS about 65% of QCOR net sales* • Estimated $150M annualized run-rate* – About 450 prescribers in Q3 – September was a record month • October 2011 – New, paid Rxs similar to Q3 monthly
Slide 12: Acthar and Nephrotic Syndrome (NS)
12 • Characterized by excessive spilling of protein from the kidneys into the urine (proteinuria) • Can result in end-stage renal disease (ESRD), dialysis, transplant • Significant unmet need – Few treatment options • Treatment for 4-6+ months* – Longer course of therapy creates future vial demand •
Slide 13: NS Scripts – Off to a Good Start
13 NS Scripts – Off to a Good Start New Paid Rxs Notes: Historical trend information is not necessarily indicative of future results. Chart includes "Related Conditions" - diagnoses that are either alternative descriptions of the condition or are closely related to the medical condition which is the
Slide 14: Estimated total: 20,000-25,000 patients
Estimated total: 20,000-25,000 patients _( QUESTCOR’
Slide 15: NS Trends
15 • Initiated sales efforts in early March 2011 – Q1 2011 new, paid NS Rxs: 18 – Q2 2011 new, paid NS Rxs: 45 – Q3 2011 new, paid NS Rxs: 60 • Expanded NS selling effort: 5 to 28 NS during Q3 • Planned sales calls to increase in Q4 by 7X over Q2 • October 2011: record month for new, paid NS Rx – Ho
Slide 16: NS Phase IV Company Sponsored Study
16 • Treatment Resistant Idiopathic Membranous Nephropathy • Dose response trial – Randomized, double blinded 3 arm study with 2 different dosage regimens of Acthar and placebo – n=84 (approximate), 35 centers (approximate) – Endpoint is reduction of proteinuria • Trial milestones – “First look” dat
Slide 17: Infantile Spasms
17 • Devastating, refractory form of childhood epilepsy – Very poor developmental outcome if inadequately treated • Not responsive to standard anti-epileptic drugs • Ultra-rare orphan disorder – 1,500 to 2,000 patients annually • Typically occurs in children less than 2 years old • Characterized by
Slide 18: Acthar and IS
18 • FDA approval 10/15/10 • Crisis therapy • Treatment for 2-4 weeks* • In a randomized, single-blinded, controlled study, 87% of patients achieved overall response (no spasms and no hypsarrhythmia) at two weeks versus 29% on prednisone • $100K-$125K/Rx – About half of patients receive drug for fre
Slide 19: IS Trends
19 • Acthar currently used to treat 40-50% of IS patients • Targeting select institutions – Promotion effort being narrowed as market is maturing – Creates selling time for Acthar MS reps to target NS • Significant variability in quarterly Rxs • Q3-2011 new, paid Rxs within historic range • October
Slide 20: Total Acthar Sales Force
20 • Specialty Sales Force – Main focus on MS (time split is ~ 80%/15%/5% on MS/NS/IS) – 77 representatives, 13 regional managers, one national director • Nephrology Sales Force – Focus 100% on Nephrotic Syndrome – 28 representatives, 4 regional managers, one national director • Combined Forces will
Slide 21: Immediate Acthar Growth Opportunities
21 Immediate Acthar Growth Opportunities *Represents estimated net sales market opportunity based on internal company estimates MS NS IS Build on sales momentum, good market headroom Market size- $500M+* Significantly expanded selling effort to 28 reps during Q3 Market size- $1B+* Targeted sales str
Slide 22: Systemic Lupus Erythematosus (Lupus)
22 • High unmet need • Serious health risk if unsuccessfully treated • Difficult to treat • Multiple on-label indications for Acthar – Exacerbations – Maintenance therapy – Lupus nephritis • Large patient population Systemic Lupus Erythematosus (Lupus) High unmet need Serious health risk if unsucces
Slide 23: Financials
23 Financials Profitable Debt Free Cash Flow Positive Profitable Debt Free Cash Flow Positive
Slide 24: Q3-2011 Financial Results
24 Q3-2011 Financial Results Net Sales ($M) Gross Margin Operating Income ($M) Fully Diluted, GAAP EPS $ 59.8 94% $33.6 $0.35 $31.3 93% $16.8 $0.18 Q3-2011 Q3-2010 Record Net Sales (up 91%) and Solid Earnings (EPS up 94%) Net Sales ($M) Gross Margin Operating Income ($M) Fully Diluted, GAAP EPS $ 59
Slide 25: Questcor is Cash Flow Positive
25 Questcor is Cash Flow Positive Cash / ST Investments Accounts Receivable $180M* $24M 10/21/11 Debt-free balance sheet *After return of $78 million of cash to shareholders through share repurchases. Cash / ST Investments Accounts Receivable $180M* $24M 10/21/11 Debt-free balance sheet
Slide 26: Share Repurchases
26 Share Repurchases: 15 Million Shares • 2.2 Million Preferred share buyback • 13.2 Common share buyback • $78 million returned to shareholders in stock buybacks • 62.7 million shares currently outstanding • 4.3 million shares remain on buyback authorization Repurchased shares significantly improve
Slide 27: Go Forward Plan - Sell More Acthar
27 • Sustain effort and momentum with MS • Expand NS selling effort • Maintain and gradually grow IS sales • Explore Systemic Lupus Erythematosus (Lupus) as another vertical market • Develop other markets for Acthar – Acthar is its own pipeline with many other on-label and many possible other therap
Slide 28: Investment Highlights
28 Investment Highlights Acthar has sustainable competitive advantages-without FDA approval risk Acthar is approved for 19 indications-many in large markets with sizable unmet need Sales in MS and NS are growing rapidly, yet market penetration is low Developing new vertical market Lupus High margins
Slide 29: November 2011
NASDAQ: QCOR November 2011 NASDAQ: QCOR November 2011
Questcor Pharmaceuticals — Investor Presentation (November 2011) on 6ix